Healthcare Resource Consumptions of Patients with Atopic Dermatitis through Italian Administrative Healthcare Data

Speaker(s)

Calabria S1, Ronconi G2, Dondi L2, Dondi L2, Dell'Anno I2, Esposito I3, Scattareggia M4, Rogliani P5, Trimarchi M6, Naldi L7, Martini N2
1Fondazione Ricerca e Salute (ReS), Roma, Italy, 2Fondazione Ricerca e Salute (ReS), Rome, Italy, 3Drugs & Health srl, Rome, Italy, 4ASST Fatebenefratelli Sacco, Milan, Italy, 5Università degli Studi di Roma Tor Vergata, Rome, Italy, 6Università della Svizzera italiana, Lugano, Switzerland, 7San Bortolo Hospital, Vicenza, Italy

Presentation Documents

OBJECTIVES: To assess the healthcare resource consumption of adults before and after dupilumab treatment for atopic dermatitis (AD), from the perspective of the Italian National Health Service (INHS).

METHODS: From the Fondazione Ricerca e Salute’s (ReS) database (administrative healthcare data of ~5 million inhabitants/year), adults treated with dupilumab from 1st September 2018 to 1st December 2020 (index date) - when AD was the only reimbursed indication - and analysable up to 5 years back, were identified. At the baseline, age, sex and comorbidities were described. Within 12 months before and after the index date, concomitant drugs, overnight all-cause hospitalizations, local outpatient all-cause specialist services and mean direct costs reimbursed by the INHS were assessed.

RESULTS: Out of 337 adults treated with dupilumab (55% males; mean age 43±19), 68% (228/337) had ±12 months of follow-up available, respectively. Asthma was a very common comorbidity (23%; 79/337 patients). Within 12 months before and after the dispensation of dupilumab, the rates of patients treated with nearly all concomitant therapeutic groups reduced: antibacterials (from 59% to 50%), systemic corticosteroids (from 55% to 29%), antihistamines (from 54% to 38%) and cyclosporine (from 52% to 7%). A similar trend was observed in the subgroup of patients with asthma as comorbidity. Within 12 months before and after dupilumab dispensation, patients hospitalized halved from 14% to 7% and subjects receiving local outpatient specialist care reduced from 72% to 65%, respectively. The mean direct total cost for the healthcare reimbursed by the INHS for each patient treated with dupilumab, net of dupilumab cost, reduced from € 1384 to € 773 within 12 months before and after the dupilumab dispensation, respectively.

CONCLUSIONS: Before dupilumab, observed patients had a higher healthcare resource consumption and direct INHS costs than during the following 12 months.

Code

EPH257

Topic

Economic Evaluation, Health Policy & Regulatory, Study Approaches

Topic Subcategory

Public Spending & National Health Expenditures

Disease

Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Sensory System Disorders (Ear, Eye, Dental, Skin)